Results 141 to 150 of about 2,234,624 (258)

A Novel Modulator of Resistance for Oxaliplatin-Based Therapy for Colorectal Cancer: The ESCRT Family Member VPS4A

Cells
Drug resistance is still one of the main challenges for the treatment of colorectal cancer (CRC). Whilst some resistance mechanisms are well known, from the static therapy success rate, clearly, still much is undiscovered.
Noha M. Abdelrazik, Anjana Patel, Andrew Conn, Christopher W. Sutton, Sriharsha Kantamneni, Steven D. Shnyder   +5 more
doaj   +1 more source

Impact of RAS/RAF Mutations on Metastatic Treatment Response Following Total Neoadjuvant Therapy in Patients With Stage IV Rectal Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
There is limited understanding of the impact of underlying RAS/RAF mutational status on total neoadjuvant therapy metastatic tumor response rates in curative Stage IV rectal cancer patients. Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients and disease progression was higher in patients harboring RAS ...
Tracy R. Fitzsimmons, Z. Bunjo, E. L. Neo, A. Badiei, M. Penniment, S. Selva‐Nayagam, A. Ruszkiewicz, J. Wong, T. Sammour   +8 more
wiley   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Roux‐en‐Y Reconstruction After Esophagectomy for Postoperative Functional Complaints: A Case Series

ANZ Journal of Surgery, EarlyView.
Functional complaints affect half of esophagectomy patients, with no standard treatment. In nine patients, Roux‐en‐Y reconstruction for obstruction, redundant conduit, and weight loss was safely performed, with one major complication and no Grade 4 out of five events. Complete symptom resolution reached 67% at 3 months and 89% at 1 year.
Donika Zogaj, Stefan H. E. M. Clermonts, Frederieke A. Dijkstra, Boudewijn van Etten, Roy J. J. Verhage, Jenneke T. H. Hamminga, Jan Willem Haveman   +6 more
wiley   +1 more source

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

tRNA‐Derived Small RNAs in Digestive Cancers: From Translational Regulation to Immune and Extracellular Communication

Cancer Science, EarlyView.
tRNA‐derived small RNAs (tsRNAs) function in digestive cancers across three scales: intracellular translational and metabolic control, extracellular vesicle–mediated immune remodeling, and systemic and host–microbe communication. This review organizes these mechanisms by evidence strength, from well‐established intracellular roles to emerging ...
Wang Xitan, Li Han
wiley   +1 more source

Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.

, 2012
BACKGROUND: Clinical studies have suggested that the epidermal growth factor receptor (EGFR)-inhibiting antibody cetuximab may have better effect in the third-line treatment of metastatic colorectal cancer, after failure of standard chemotherapy ...
Ekblad, Lars, Johnsson, Anders
core   +1 more source